{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T07:58:04Z","timestamp":1780991884528,"version":"3.54.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T00:00:00Z","timestamp":1778716800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T00:00:00Z","timestamp":1778716800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003500","name":"Universit\u00e0 degli Studi di Padova","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003500","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Depression is an underrecognized and undertreated condition in Parkinson\u2019s disease (PD). The development of updated, individualized management strategies represents an important unmet need for clinicians and care providers. This review examines the use of trazodone, focusing on its mechanism of action, and proposes a practical algorithm for its use in the management of depression in patients with PD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>Seven neurologists, experts in movement disorders took part in a structured panel on depression management to exchange ideas and experiences for the implementation of best practice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The experts agreed that trazodone can be beneficial in PD patients with comorbid depression. The treatment algorithm proposed considers patients in early or more advanced stages of PD. In early stages with mood alterations and anxiety, the suggested treatments are a mood stabilizer, trazodone, or a tricyclic antidepressant. Serotonergic therapy or an SNRI should be considered for patients with low mood but no agitation. In presence of depressive mood with predominant insomnia, high-dose trazodone should be considered along with mirtazapine. In more advanced stages, in the presence of cognitive deficits without agitation low to medium dose trazodone can be considered along with mirtazapine. In case of cognitive deficits with agitation, low to medium dose trazodone is suggested.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The proposed algorithm may assist neurologists in the management of depression in patients with PD by providing specific recommendations on the role of trazodone across different clinical scenarios, allowing for individualized treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10072-026-08978-6","type":"journal-article","created":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T03:07:15Z","timestamp":1778728035000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Trazodone for management of depression in Parkinson\u2019s disease: expert opinion and proposal for a treatment algorithm"],"prefix":"10.1007","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1040-2807","authenticated-orcid":false,"given":"Angelo","family":"Antonini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Rita","family":"Bentivoglio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna","family":"Calandra-Buonaura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Ceravolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Leta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Teresa","family":"Pellecchia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Pilotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Nicoletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,14]]},"reference":[{"issue":"12","key":"8978_CR1","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1038\/s41582-024-01034-x","volume":"20","author":"F Stocchi","year":"2024","unstructured":"Stocchi F, Bravi D, Emmi A, Antonini A (2024) Parkinson disease therapy: current strategies and future research priorities. Nat Rev Neurol 20(12):695\u2013707. https:\/\/doi.org\/10.1038\/s41582-024-01034-x","journal-title":"Nat Rev Neurol"},{"issue":"7","key":"8978_CR2","doi-asserted-by":"publisher","first-page":"e464","DOI":"10.1016\/S2666-7568(24)00094-1","volume":"5","author":"J Zhu","year":"2024","unstructured":"Zhu J, Cui Y, Zhang J et al (2024) Temporal trends in the prevalence of Parkinson\u2019s disease from 1980 to 2023: a systematic review and meta-analysis. Lancet Healthy Longev 5(7):e464\u2013e79. https:\/\/doi.org\/10.1016\/S2666-7568(24)00094-1","journal-title":"Lancet Healthy Longev"},{"issue":"10423","key":"8978_CR3","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/S0140-6736(23)01419-8","volume":"403","author":"Y Ben-Shlomo","year":"2024","unstructured":"Ben-Shlomo Y, Darweesh S, Llibre-Guerra J et al (2024) The epidemiology of Parkinson\u2019s disease. Lancet 403(10423):283\u201392. https:\/\/doi.org\/10.1016\/S0140-6736(23)01419-8","journal-title":"Lancet"},{"key":"8978_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2022.101840","volume":"85","author":"MH Ahmad","year":"2023","unstructured":"Ahmad MH, Rizvi MA, Ali M et al (2023) Neurobiology of depression in Parkinson\u2019s disease: Insights into epidemiology, molecular mechanisms and treatment strategies. Ageing Res Rev 85:101840. https:\/\/doi.org\/10.1016\/j.arr.2022.101840","journal-title":"Ageing Res Rev"},{"key":"8978_CR5","unstructured":"Fredericks D, Norton JC, Atchison C et al (2017) Parkinson\u2019s disease and Parkinson\u2019s disease psychosis: a perspective on the challenges, treatments, and economic burden Am J Manag Care23(5 Suppl):S83-S92"},{"key":"8978_CR6","doi-asserted-by":"publisher","unstructured":"Barone P, Antonini A, Colosimo C et al (2009) The PRIAMO study: a multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson\u2019s disease Mov Disord. 24(11):1641\u20131649. https:\/\/doi.org\/10.1002\/mds.22643","DOI":"10.1002\/mds.22643"},{"issue":"4","key":"8978_CR7","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1002\/mdc3.12507","volume":"4","author":"SE Starkstein","year":"2017","unstructured":"Starkstein SE, Brockman S (2017) Management of depression in Parkinson\u2019s disease: a systematic review. Mov Disord Clin Pract 4(4):470\u20137. https:\/\/doi.org\/10.1002\/mdc3.12507","journal-title":"Mov Disord Clin Pract"},{"issue":"4","key":"8978_CR8","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000041275","volume":"104","author":"J Wu","year":"2025","unstructured":"Wu J, Liu M, Chen M et al (2025) Factors associated with higher caregiver burden among informal caregivers of Parkinson\u2019s disease: a systematic review. Medicine Baltimore 104(4):e41275. https:\/\/doi.org\/10.1097\/MD.0000000000041275","journal-title":"Medicine Baltimore"},{"issue":"15","key":"8978_CR9","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1080\/14656566.2023.2240228","volume":"24","author":"M Campagnolo","year":"2023","unstructured":"Campagnolo M, Emmi A, Biundo R, Fiorenzato E, Batzu L, Chaudhuri KR, Antonini A (2023) The pharmacological management of the behavioral aspects of Parkinson\u2019s disease: an update. Expert Opin Pharmacother 24(15):1693\u20131701. https:\/\/doi.org\/10.1080\/14656566.2023.2240228","journal-title":"Expert Opin Pharmacother"},{"key":"8978_CR10","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.jad.2015.09.005","volume":"189","author":"EI Fried","year":"2016","unstructured":"Fried EI, Epskamp S, Nesse RM et al (2016) What are \u201cgood\u201d depression symptoms? Comparing the centrality of DSM and non-DSM symptoms of depression in a network analysis. J Affect Disord 189:314\u201320. https:\/\/doi.org\/10.1016\/j.jad.2015.09.005","journal-title":"J Affect Disord"},{"key":"8978_CR11","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.jad.2014.10.010","volume":"172","author":"EI Fried","year":"2015","unstructured":"Fried EI, Nesse RM (2015) Depression is not a consistent syndrome: An investigation of unique symptom patterns in the STAR*D study. J Affect Disord 172:96\u2013102. https:\/\/doi.org\/10.1016\/j.jad.2014.10.010","journal-title":"J Affect Disord"},{"issue":"2","key":"8978_CR12","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1002\/mds.20723","volume":"21","author":"L Marsh","year":"2006","unstructured":"Marsh L, McDonald WM, Cummings J et al (2006) Provisional diagnostic criteria for depression in Parkinson\u2019s disease: report of an NINDS\/NIMH work group. Mov Disord 21(2):148\u201358. https:\/\/doi.org\/10.1002\/mds.20723","journal-title":"Mov Disord"},{"key":"8978_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/medicina59081454","author":"E Angelopoulou","year":"2023","unstructured":"Angelopoulou E, Stanitsa E, Karpodini CC et al (2023) Pharmacological and non-pharmacological treatments for depression in Parkinson\u2019s disease: an updated review. Medicina (Kaunas). https:\/\/doi.org\/10.3390\/medicina59081454","journal-title":"Medicina (Kaunas)"},{"issue":"8","key":"8978_CR14","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1002\/mds.21333","volume":"22","author":"A Schrag","year":"2007","unstructured":"Schrag A, Barone P, Brown RG et al (2007) Depression rating scales in Parkinson\u2019s disease: critique and recommendations. Mov Disord 22(8):1077\u201392. https:\/\/doi.org\/10.1002\/mds.21333","journal-title":"Mov Disord"},{"issue":"8","key":"8978_CR15","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1111\/ene.12724","volume":"22","author":"P Barone","year":"2015","unstructured":"Barone P, Santangelo G, Morgante L et al (2015) A randomized clinical trial to evaluate the effects of rasagiline on depressive symptoms in non-demented Parkinson\u2019s disease patients. Eur J Neurol 22(8):1184\u201391. https:\/\/doi.org\/10.1111\/ene.12724","journal-title":"Eur J Neurol"},{"issue":"7","key":"8978_CR16","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/j.parkreldis.2013.02.018","volume":"19","author":"K Ray Chaudhuri","year":"2013","unstructured":"Ray Chaudhuri K, Martinez-Martin P, Antonini A et al (2013) Rotigotine and specific non-motor symptoms of Parkinson\u2019s disease: post hoc analysis of RECOVER. Parkinsonism Relat Disord 19(7):660\u20135. https:\/\/doi.org\/10.1016\/j.parkreldis.2013.02.018","journal-title":"Parkinsonism Relat Disord"},{"issue":"6","key":"8978_CR17","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/S1474-4422(10)70106-X","volume":"9","author":"P Barone","year":"2010","unstructured":"Barone P, Poewe W, Albrecht S et al (2010) Pramipexole for the treatment of depressive symptoms in patients with Parkinson\u2019s disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 9(6):573\u201380. https:\/\/doi.org\/10.1016\/S1474-4422(10)70106-X","journal-title":"Lancet Neurol"},{"issue":"8","key":"8978_CR18","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.27750","volume":"14","author":"R Chikatimalla","year":"2022","unstructured":"Chikatimalla R, Dasaradhan T, Koneti J et al (2022) Depression in Parkinson\u2019s Disease: A Narrative Review. Cureus 14(8):e27750. https:\/\/doi.org\/10.7759\/cureus.27750","journal-title":"Cureus"},{"issue":"2B","key":"8978_CR19","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1590\/s0004-282x2009000300007","volume":"67","author":"AL Werneck","year":"2009","unstructured":"Werneck AL, Rosso AL, Vincent MB (2009) The use of an antagonist 5-HT2a\/c for depression and motor function in Parkinson\u2019 disease. Arq Neuropsiquiatr 67(2B):407\u201312. https:\/\/doi.org\/10.1590\/s0004-282x2009000300007","journal-title":"Arq Neuropsiquiatr"},{"issue":"4","key":"8978_CR20","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1708\/3202.31796","volume":"54","author":"A Cuomo","year":"2019","unstructured":"Cuomo A, Ballerini A, Bruni AC et al (2019) Clinical guidance for the use of trazodone in major depressive disorder and concomitant conditions: pharmacology and clinical practice. Riv Psichiatr 54(4):137\u201349. https:\/\/doi.org\/10.1708\/3202.31796","journal-title":"Riv Psichiatr"},{"issue":"8","key":"8978_CR21","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1111\/ene.14933","volume":"28","author":"K Aleksovska","year":"2021","unstructured":"Guideline Production Group of the European Academy of N, Aleksovska K, Bassetti CLA et al (2021) Guidelines should be guidelines: Time to leave the terms consensus and position for other purposes. Eur J Neurol 28(8):2461\u20132466. https:\/\/doi.org\/10.1111\/ene.14933","journal-title":"Eur J Neurol"},{"issue":"12","key":"8978_CR22","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1007\/s40263-012-0010-5","volume":"26","author":"A Fagiolini","year":"2012","unstructured":"Fagiolini A, Comandini A, Catena Dell\u2019Osso M et al (2012) Rediscovering trazodone for the treatment of major depressive disorder. CNS Drugs 26(12):1033\u201349. https:\/\/doi.org\/10.1007\/s40263-012-0010-5","journal-title":"CNS Drugs"},{"issue":"10","key":"8978_CR23","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1017\/s1092852900024020","volume":"14","author":"SM Stahl","year":"2009","unstructured":"Stahl SM (2009) Mechanism of action of trazodone: a multifunctional drug. CNS Spectr 14(10):536\u201346. https:\/\/doi.org\/10.1017\/s1092852900024020","journal-title":"CNS Spectr"},{"issue":"3","key":"8978_CR24","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1177\/0269881105051526","volume":"19","author":"Y Odagaki","year":"2005","unstructured":"Odagaki Y, Toyoshima R, Yamauchi T (2005) Trazodone and its active metabolite m-chlorophenylpiperazine as partial agonists at 5-HT1A receptors assessed by [35S]GTPgammaS binding. J Psychopharmacol 19(3):235\u201341. https:\/\/doi.org\/10.1177\/0269881105051526","journal-title":"J Psychopharmacol"},{"issue":"2","key":"8978_CR25","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/sj.npp.1300057","volume":"28","author":"GJ Marek","year":"2003","unstructured":"Marek GJ, Carpenter LL, McDougle CJ et al (2003) Synergistic action of 5-HT2A antagonists and selective serotonin reuptake inhibitors in neuropsychiatric disorders. Neuropsychopharmacology 28(2):402\u201312. https:\/\/doi.org\/10.1038\/sj.npp.1300057","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"8978_CR26","first-page":"83","volume":"53","author":"AA Nierenberg","year":"1992","unstructured":"Nierenberg AA, Cole JO, Glass L (1992) Possible trazodone potentiation of fluoxetine: a case series. J Clin Psychiatry 53(3):83\u201385","journal-title":"J Clin Psychiatry"},{"issue":"3","key":"8978_CR27","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/s0014-2999(99)00644-5","volume":"383","author":"M Pazzagli","year":"1999","unstructured":"Pazzagli M, Giovannini MG, Pepeu G (1999) Trazodone increases extracellular serotonin levels in the frontal cortex of rats. Eur J Pharmacol 383(3):249\u2013257. https:\/\/doi.org\/10.1016\/s0014-2999(99)00644-5","journal-title":"Eur J Pharmacol"},{"key":"8978_CR28","first-page":"18","volume":"13","author":"ME Thase","year":"2003","unstructured":"Thase ME (2003) Evaluating antidepressant therapies: remission as the optimal outcome. J Clin Psychiatry64 Suppl 13:18\u201325","journal-title":"J Clin Psychiatry64 Suppl"},{"issue":"12","key":"8978_CR29","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/s0166-2236(00)02002-6","volume":"24","author":"CB Saper","year":"2001","unstructured":"Saper CB, Chou TC, Scammell TE (2001) The sleep switch: hypothalamic control of sleep and wakefulness. Trends Neurosci 24(12):726\u201331. https:\/\/doi.org\/10.1016\/s0166-2236(00)02002-6","journal-title":"Trends Neurosci"},{"issue":"12","key":"8978_CR30","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1017\/s1092852900017089","volume":"13","author":"SM Stahl","year":"2008","unstructured":"Stahl SM (2008) Selective histamine H1 antagonism: novel hypnotic and pharmacologic actions challenge classical notions of antihistamines. CNS Spectr 13(12):1027\u201338. https:\/\/doi.org\/10.1017\/s1092852900017089","journal-title":"CNS Spectr"},{"issue":"1","key":"8978_CR31","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1177\/0269881117742101","volume":"32","author":"L Settimo","year":"2018","unstructured":"Settimo L, Taylor D (2018) Evaluating the dose-dependent mechanism of action of trazodone by estimation of occupancies for different brain neurotransmitter targets. J Psychopharmacol 32(1):96\u2013104","journal-title":"J Psychopharmacol"},{"key":"8978_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.36150\/2499-6564-N320","volume":"69","author":"A Cuomo","year":"2021","unstructured":"Cuomo A, Bianchetti A, Cagnin A et al (2021) Trazodone: a multifunctional antidepressant. Evaluation of its properties and real-world use. J Gerontol Geriatr 69:1\u201310","journal-title":"J Gerontol Geriatr"},{"issue":"3","key":"8978_CR33","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1097\/YIC.0000000000000304","volume":"35","author":"A Fagiolini","year":"2020","unstructured":"Fagiolini A, Albert U, Ferrando L et al (2020) A randomized, double-blind study comparing the efficacy and safety of trazodone once-a-day and venlafaxine extended-release for the treatment of patients with major depressive disorder. Int Clin Psychopharmacol 35(3):137\u201346","journal-title":"Int Clin Psychopharmacol"},{"key":"8978_CR34","unstructured":"Trazodone Summary of product characteristics"},{"key":"8978_CR35","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2020.595623","volume":"11","author":"L Liu","year":"2020","unstructured":"Liu L, Jian P, Zhou Y et al (2020) Is the long-term use of benzodiazepines associated with worse cognition performance in highly educated older adults? Front Psychiatry 11:595623. https:\/\/doi.org\/10.3389\/fpsyt.2020.595623","journal-title":"Front Psychiatry"},{"issue":"5","key":"8978_CR36","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1159\/000525988","volume":"28","author":"SPG Zetsen","year":"2022","unstructured":"Zetsen SPG, Schellekens AFA, Paling EP et al (2022) Cognitive functioning in long-term benzodiazepine users. Eur Addict Res 28(5):377\u201381. https:\/\/doi.org\/10.1159\/000525988","journal-title":"Eur Addict Res"},{"key":"8978_CR37","doi-asserted-by":"publisher","unstructured":"Burunsuz O, Ozdengul F, Gica S et al (2022) Investigation of the effect of trazodone on spontaneous and acetylcholine-induced bladder detrusor smooth muscle contractions Dusunen Adam Journal of Psychiatry and Neurological Sciences35:43\u2009\u2013\u20097. https:\/\/doi.org\/10.14744\/dajpns.2022.00170","DOI":"10.14744\/dajpns.2022.00170"},{"key":"8978_CR38","unstructured":"Jaffer KY, Chang T, Vanle B et al (2017) Trazodone for Insomnia: A Systematic Review Innov Clin Neurosci. 14(7\u20138):24\u201334"},{"key":"8978_CR39","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.ajp.2017.11.028","volume":"32","author":"K Wada","year":"2018","unstructured":"Wada K, Morita Y, Iwamoto T et al (2018) First- and second-line pharmacological treatment for delirium in general hospital setting-retrospective analysis. Asian J Psychiatr 32:50\u20133","journal-title":"Asian J Psychiatr"},{"issue":"3","key":"8978_CR40","doi-asserted-by":"publisher","first-page":"S149","DOI":"10.1002\/ana.10514","volume":"53","author":"AH Schapira","year":"2003","unstructured":"Schapira AH, Olanow CW (2003) Rationale for the use of dopamine agonists as neuroprotective agents in Parkinson\u2019s disease. Ann Neurol 53(3):S149-57. https:\/\/doi.org\/10.1002\/ana.10514","journal-title":"Ann Neurol"},{"issue":"10","key":"8978_CR41","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1007\/s00702-024-02807-w","volume":"131","author":"D Weise","year":"2024","unstructured":"Weise D, Claus I, Dresel C et al (2024) Multidisciplinary care in Parkinson\u2019s disease. Journal of Neural Transmission 131(10):1217\u201327","journal-title":"Journal of Neural Transmission"},{"issue":"8","key":"8978_CR42","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1002\/mds.20895","volume":"21","author":"A Antonini","year":"2006","unstructured":"Antonini A, Tesei S, Zecchinelli A et al (2006) Randomized study of sertraline and low-dose amitriptyline in patients with Parkinson\u2019s disease and depression: effect on quality of life. Mov Disord 21(8):1119\u201322","journal-title":"Mov Disord"},{"issue":"5","key":"8978_CR43","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1007\/s00415-006-0067-5","volume":"253","author":"P Barone","year":"2006","unstructured":"Barone P, Scarzella L, Marconi R et al (2006) Pramipexole versus sertraline in the treatment of depression in Parkinson\u2019s disease: a national multicenter parallel-group randomized study. J Neurol 253(5):601\u20137","journal-title":"J Neurol"},{"issue":"5","key":"8978_CR44","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1080\/14737175.2025.2485337","volume":"25","author":"L Rigon","year":"2025","unstructured":"Rigon L, Fogliano C, Chaudhuri KR, Poplawska-Domaszewicz K, Falup-Pecurariu C, Murasan I, Wolfschlag M, Odin P, Antonini A (2025) Managing impulse control and related behavioral disorders in Parkinson\u2019s disease: where we are in 2025? Expert Rev Neurother 25(5):537\u2013554. https:\/\/doi.org\/10.1080\/14737175.2025.2485337","journal-title":"Expert Rev Neurother"},{"issue":"1","key":"8978_CR45","doi-asserted-by":"publisher","first-page":"88","DOI":"10.3758\/s13415-018-00646-3","volume":"19","author":"S Kobayashi","year":"2019","unstructured":"Kobayashi S, Asano K, Matsuda N et al (2019) Dopaminergic influences on risk preferences of Parkinson\u2019s disease patients. Cogn Affect Behav Neurosci 19(1):88\u201397","journal-title":"Cogn Affect Behav Neurosci"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-026-08978-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-026-08978-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-026-08978-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T07:06:01Z","timestamp":1780988761000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10072-026-08978-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,14]]},"references-count":45,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["8978"],"URL":"https:\/\/doi.org\/10.1007\/s10072-026-08978-6","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,14]]},"assertion":[{"value":"31 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No ethical approval was required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical"}},{"value":"Angelo Antonini reports personal consultancy fees from UCB, Bayer, Britannia, AbbVie, Angelini, Zambon, Bial, Theravance Biopharma, AskBio, Novartis, Roche; he receives research support from Horizon2020, Italian Ministry of Education (MOE), Italian Ministry of University and Research (MUR), Pezzoli Parkinson Foundation. All other authors report no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"492"}}